Results 171 to 180 of about 137,198 (351)
Sycosis Barbae Treated With Bimekizumab
ABSTRACT Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31‐year‐old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)‐17A and IL‐17F.
Matiar Madanchi +3 more
wiley +1 more source
ABSTRACT Patients diagnosed with gestational trophoblastic diseases (GTD) can develop malignant gestational trophoblastic neoplasia (GTN). ß‐hCG monitoring is important in the early detection of GTN. The primary outcome of this study was to describe ß‐hCG monitoring completion rates and time from GTN diagnosis to chemotherapy commencement for patients ...
Harrison Odgers +2 more
wiley +1 more source
This study investigates the effect of IL‐5 vaccination on allergen‐specific IgE levels, as well as mRNA and protein expression of Th1/Th2‐associated cytokines using a murine OVA skin allergy model and the naturally occurring skin allergy IBH in horses.
Fadi Jebbawi +12 more
wiley +1 more source
Alopecia Areata of the Moustache of Dental Origin [PDF]
NULL AUTHOR_ID
openalex +1 more source
This study explores the bidirectional associations between SD and EBDs in a cohort of 5,083,689 individuals in a US administrative claims database. Positive bidirectional associations were found between SD and many EBDs of the skin, respiratory, gastrointestinal, and ocular surfaces. Our results support the EBT as a shared driver of EBD pathogenesis at
Sabrina Meng +6 more
wiley +1 more source
This study investigates the effect of IL‐33 and Hymenoptera venom on mast cell cytokine profiles under venom immunotherapy (VIT)‐like conditions. Our in vitro model of VIT‐like mast cell stimulation demonstrates a modulatory effect of IL‐33 on the secreted mast cell cytokine profile.
Andrea R. Teufelberger +3 more
wiley +1 more source
Patients' knowledge, attitude, and practice regarding alopecia: a cross-sectional study in Hebei, China. [PDF]
Li H +5 more
europepmc +1 more source

